Real-world data on persons living with HIV (PLWH) switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) while virologically suppressed: 96-week data from the Icona cohort

被引：0

作者：

Monforte, A. d'Arminio ^{[1
]}

Tavelli, A. ^{[1
]}

Cingolani, A. ^{[2
,3
]}

Taramasso, L. ^{[4
]}

Mussini, C. ^{[5
]}

Piconi, S. ^{[6
]}

Calcagno, A. ^{[7
,8
]}

Orofino, G. ^{[9
]}

Cicalini, S. ^{[10
]}

Castagna, A. ^{[11
,12
]}

Ceccherini-Silberstein, F. ^{[13
]}

Gori, A. ^{[14
,15
]}

Guaraldi, G. ^{[5
]}

Antinori, A. ^{[10
]}

机构：

[1] Icona Fdn, Milan, Italy

[2] Fdn Policlin Univ Agostino Gemelli IRCCS, Infect Dis Unit, Rome, Italy

[3] Univ Cattolica Sacro Cuore, Dept Safety & Bioeth, Rome, Italy

[4] Univ Genoa, Osped Policlin San Martino IRCCS, Unit Infect Dis, Genoa, Italy

[5] Univ Modena & Reggio Emilia, AOU Modena, Infect & Trop Dis Unit, Modena, Italy

[6] ASST Lecco, Infect Dis Unit, Lecce, Italy

[7] Osped Amedeo Savoia, Unit Infect Dis, Turin, Italy

[8] Univ Turin, Dept Med Sci, Turin, Italy

[9] ASL Citta Torino, Div A Infect Dis, Osped Amedeo Savoia, Turin, Italy

[10] Natl Inst Infect Dis Lazzaro Spallanzani IRCCS, Clin Dept HIV, AIDS Unit, Rome, Italy

[11] IRCCS San Raffaele Sci Inst, Infect Dis Unit, Milan, Italy

[12] Univ Vita Salute San Raffaele, Milan, Italy

[13] Univ Roma Tor Vergata, Dept Expt Med, Rome, Italy

[14] ASST Fatebenefratelli Sacco, Unit Infect Dis 2, Milan, Italy

[15] Univ Milan, Milan, Italy

来源：

HIV MEDICINE | 2023年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

843

引用

下载

页码：157 / 159

页数：3

共 48 条

[31] Patient-reported outcome (PRO) measures at 12 months (12M) in a real-world cohort of people living with HIV (PLWH) with a high prevalence of comorbidities receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Europe, Canada, and Israel
Brunetta, J.
Monforte, A. D'Arminio
Elbirt, D.
Postel, N.
van Welzen, B.
Zeggagh, J.
Milinkovic, A.
Marongiu, A.
Heinzkill, M.
Thorpe, D.
Cornejo, A. Torres
Antela, A.
HIV MEDICINE, 2021, 22 : 108 - 110
[32] The clinical relevance of potential drug-drug interactions with bictegravir/emtricitabine/tenofovir alafenamide - Real-world data from the German IQVIA prescription database
Umland, T.
Stellbrink, H.
Calvo, M.
Zahn, A.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 88 - 90
[33] Cardiovascular Disease Risk in a Cohort of Virologically Suppressed People Living with HIV Switching to Doravirine: Preliminary Data from the Real Life
Iannone, Valentina
Farinacci, Damiano
D'Angelillo, Anna
Dusina, Alex
Lamanna, Francesco
Passerotto, Rosanna
Baldin, Gianmaria
Visconti, Elena
Tamburrini, Enrica
Borghetti, Alberto
Di Giambenedetto, Simona
Ciccullo, Arturo
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2022, 38 (11) : 878 - 880
[34] Switch from tenofovir disoproxil fumarate (TDF)- to tenofovir alafenamide (TAF)-based regimens in clinical practice: real-world data of the German PROPHET cohort study
Bickel, M.
Wyen, C.
Spinner, C.
Baumgarten, A.
Jaeger, H.
Postel, N.
Wolf, E.
Hoffmann, C.
Esser, S.
Klauke, S.
Schewe, K.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
[35] Real-world clinical outcomes of HIV-1 virologically suppressed adults on bictegravir/emtricitabine/tenofovir alafenamide who switched to long-acting intramuscular cabotegravir plus rilpivirine at 12, 24, and 48-weeks
Nasser, K.
Valentin, A. -M.
Ramgopal, M.
HIV MEDICINE, 2023, 24 : 161 - 162
[36] Clinical experience of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in real life practice: data from the Turkish HIV-TR cohort
Korten, V.
Inan, A.
Akalin, H.
Gokengin, D.
Kaya, B.
Inan, D.
Ozdemir, H. Ozkan
Azak, E.
Dogru, A.
Dokuzoguz, B.
Yildirmak, T.
Kose, S.
Karaoglan, I.
HIV MEDICINE, 2019, 20 : 58 - 58
[37] Phase 3, randomised, controlled trial of switching to fixed-dose bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from boosted protease inhibitor-based regimens in virologically suppressed adults: a sub-analysis of week-48 lipid results
Fox, J.
Post, F. A.
Johnson, M.
Daar, E. S.
DeJesus, E.
Liu, Y-P
Graham, H.
Cheng, A.
Martin, H.
Quirk, E.
HIV MEDICINE, 2018, 19 : S84 - S85
[38] Two year outcomes of dolutegravir/rilpivirine in virologically suppressed HIV-infected PLHIV: real-world data from the German JUNGLE cohort
Ummard-Berger, K.
Wyen, C.
Schabaz, F.
Hillenbrand, H.
Beer, D.
Schneeweiss, S.
Weinberg, G.
Postel, N.
Westermayer, B.
Dymek, K. M.
Scherzer, J.
HIV MEDICINE, 2021, 22 : 76 - 76
[39] Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
Eron, Joseph J.
Orkin, Chloe
Cunningham, Douglas
Pulido, Federico
Post, Frank A.
De Wit, Stephane
Lathouwers, Erkki
Hufkens, Veerle
Jezorwski, John
Petrovic, Romana
Brown, Kimberley
Van Landuyt, Erika
Opsomer, Magda
De Wit, S.
Florence, E.
Moutschen, M.
Van Wijngaerden, E.
Vandekerckhove, L.
Vandercam, B.
Brunetta, J.
Conway, B.
Klein, M.
Murphy, D.
Rachlis, A.
Shafran, S.
Walmsley, S.
Ajana, F.
Cotte, L.
Girardy, P. -M.
Katlama, C.
Molina, J. -M.
Poizot-Martin, I.
Raffi, F.
Rey, D.
Reynes, J.
Teicher, E.
Yazdanpanah, Y.
Gasiorowski, J.
Halota, W.
Horban, A.
Piekarska, A.
Witor, A.
Arribas, J. R.
Perez-Valero, I.
Berenguer, J.
Casado, J.
Gatell, J. M.
Gutierrez, F.
Galindo, M. J.
Gutierrez, M. D. M.
ANTIVIRAL RESEARCH, 2019, 170
[40] 12-months outcomes of dolutegravir/rilpivirine in virologically suppressed HIV-infected patients: real-world data from the German JUNGLE cohort
Noe, S.
Ummard-Berger, K.
Hillenbrand, H.
Beer, D.
Wyen, C.
Pauli, R.
Postel, N.
Dymek, K.
Westermayer, B.
Scherzer, J.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 44 - 45

← 1 2 3 4 5 →